Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Alnylam Pharmaceuticals faces a securities fraud investigation following a significant stock price decline. On July 30, 2026, the company lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected market adoption in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.31% stock price drop, prompting a class action investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.